Botox vs Jeuveau: Which Neuromodulator to Stock and Offer

Both products are dosed in units, and the standard conversion is 1:1 for most practitioners. Jeuveau was specifically engineered using a proprietary manufacturing process (recombinant DNA technology) that differs from Botox's fermentation method, but clinical outcomes in peer-reviewed trials show no meaningful difference in onset (3–7 days), duration (3–4 months), or efficacy at equivalent units. Some practitioners report slightly faster onset with Jeuveau (5–7 days vs. 7–14 for Botox), though this is anecdotal and not universally observed. For practice purposes, treat them as interchangeable from a clinical standpoint.

Pricing and Rebate Economics

Botox commands approximately 70–75% of the U.S. aesthetic neuromodulator market. Its dominance translates to:

• Higher wholesale acquisition cost per unit (typically $12–16 per unit for practices, depending on volume tier and loyalty program)
• Robust rebate infrastructure through Alle (Allergan's loyalty platform), which offers tiered rebates, co-pay cards, and practice incentives tied to volume
• Stronger patient brand recognition and willingness to pay premium pricing

Jeuveau (Evolus) positions as the value alternative:

• Lower per-unit acquisition cost (typically $8–12 per unit, depending on volume)
• Evolus Rewards program offers rebates and volume incentives, though less mature than Alle
• Smaller installed base means fewer patients arrive pre-requesting the product by name

The math: if you charge patients $12–14 per unit (a typical median for both), your margin on Botox is narrower due to higher acquisition cost, but patient demand is higher. Jeuveau yields better per-unit margin but requires active patient education and positioning to drive uptake.

Market Share and Patient Positioning

Botox's 70%+ share reflects decades of brand dominance and direct-to-consumer marketing spend. Patients often ask for it by name. Practices that stock only Botox avoid the friction of patient education; practices that offer both can position Jeuveau as "same science, better value" to price-sensitive patients or as a loyalty incentive.

Jeuveau has gained traction among practices seeking differentiation and margin improvement, particularly in competitive markets. Its smaller market share can actually be an advantage: practices offering it stand out as informed, not following the herd.

Practical Considerations

Single-product strategy: Stock Botox if you prioritize patient convenience, brand trust, and simplicity. Alle's rebate ecosystem is mature and drives patient acquisition.

Dual-product strategy: Offer both if you have the cold-chain capacity and patient volume to justify inventory. Use Jeuveau for new patients, price-sensitive segments, or as a loyalty reward; reserve Botox for patients who specifically request it or have prior experience.

Supply and availability: Botox has never faced meaningful shortages; Jeuveau supply has been stable since launch but remains less distributed than Botox. Verify your distributor's stock before committing.

Regulatory and scope: Both require the same prescriber oversight and injection credentials (physician, PA, NP, or RN under supervision, depending on state). No compliance difference.

The Bottom Line

Choose Botox if patient demand and brand recognition are your priority and margin pressure is secondary. Choose Jeuveau if you're optimizing per-unit economics and willing to educate patients on equivalence. Many successful practices do both: Botox as the default, Jeuveau as the value play. Your distributor relationship, volume commitments, and local competitive landscape should guide the final call.